ST6GAL1 and cervical cancer: ST6GAL1, responsible for the terminal α2,6-sialylation of N-glycans, can be upregulated by HPV16 E5 oncoprotein, and its inhibition increases cisplatin sensitivity of HPV18+ cervical cancer cells (35, 47).